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CIRI-CIRI ANTIHYPERTENSIF EKSTRAK TERPIAWAI DAUN 
ORTHOSIPHON STAMINEUS BENTH. DAN NANO LIPOSOMNYA 
TERHADAP TIKUS HYPERTENSIF SPONTAN 
 
7 ABSTRAK 
Kajian ini dijalankan untuk memenuhi jurang antara amalan herba peribumi dan 
sains perubatan kontemporari ke atas kesan antihipertensi daun Orthosiphon stamineus 
(OS).  Kajian kualiti dan keselamatan bahan mentah tumbuhan diperiksa 
menggunakan analisis gravimetrik dan ujian had mikrob (MLT). Daun OS didapati 
memenuhi kualiti dari segi fizikokimia serta pencemaran mikrob. Analisis 
spektroskopi kualitatif (UV, FT-IR, FT-NIR), kromatografi (HPTLC) dan 
kromatografi kuantitatif (HPLC) telah dijalankan terhadap ekstrak OS yang berlainan 
untuk pemiawaian. Hasil kajian menunjukkan bahawa bahan kimia utama dalam 
ekstrak OS adalah fenolik dan flavonoid seperti asid rosmarinik (RA), 3-hidroksi-
5,6,7,4-metoksiflavon (TMF), sinensetin (SIN) dan  eupatorin (EUP). Tambahan lagi, 
teknik HPLC-DAD gradien yang digabungkan dengan pengekstrakan fasa pepejal 
telah dibangunkan dan disahkan untuk pengenalpastian dan pengkuantitian 17 asid 
amino bebas dalam ekstrak OS. Hasil kajian menunjukkan bahawa asid L-aspartik dan 
asid L-glutamik adalah asid amino bebas utama dalam ekstrak OS dengan 0.93 ± 0.01 
nmol/mg dan 4.01 ± 0.12 nmol/mg. Metabolit primer dan sekunder ekstrak OS telah 
dianalisis untuk menentukan jumlah flavonoid, polifenol, fosfolipid, protein, 
polisakarida dan glikosaponin. Perbezaan peratusan metabolit ini dalam setiap ekstrak 
telah ditunjukkan. Ekstrak OS yang berlainan dan sebatian piawai (RA, TMF, SIN dan 
EUP) telah dinilai dalam assai perencatan enzim penukaran angiotensin (ACE-I) 
secara in vitro. Hasil kajian menunjukkan bahawa OS-E dan EUP, pada kepekatan 50 
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µg/mL mempamerkan perencatan tertinggi (masing-masing pada 52.67 ± 0.89 dan 
73.11 ± 2.39%) terhadap ACE berbanding dengan ekstrak dan sebatian piawai lain. 
Captopril telah digunakan sebagai kawalan positif dan menunjukkan perencatan 
sebanyak 86.14 ± 2.98% pada kepekatan 6.8 ng/mL. Keupayaan mengkelat Zn2+ oleh 
RA, TMF, SIN, EUP, captopril dan OS-E telah dijalankan menggunakan reagen 
tetrametilmureksida (TMM). Hasil kajian menunjukkan OS-E dan captopril 
mempunyai keupayaan tinggi (79.42 ± 1.91 dan 100 ± 1.59) untuk mengikat dengan 
Zn2+ pada kepekatan 5 mg/mL. Antara sebatian piawai yang diuji, EUP menunjukkan 
keupayaan tertinggi dalam mengikat Zn2+ (56.03 ± 1.26%) pada kepekatan 5 mg/mL. 
Tambahan lagi, skor cantuman dan afiniti ikatan bagi sebatian penanda Zn2+ pada ACE 
telah dinilai. Hasil kajian menunjukkan bahawa EUP mempunyai tenaga afiniti 
pengikatan (ΔG) dan kecekapan ligan tertinggi dengan -6.93 kcal/mol. Seterusnya, 
ekstrak OS-E telah disediakan dalam formulasi liposom menggunakan lesitin soya 
nyah minyak (OS-EL) dan dicirikan melawan parameter berbeza. OS-EL dicirikan 
melawan parameter yang berbeza. Hasil kajian menunjukkan penghasilan liposom 
nano daripada OS-E. Farmakokinetik dan bioavailabiliti oral bagi RA, TMF, SIN dan 
EUP dalam OS-E dan OS-EL dikaji ke atas tikus Sprague Dawley (SD) menunjukkan 
peningkatan signifikan dalam keterlarutan akueus dan bioavailabiliti oral bagi RA, 
TMF, SIN dan EUP dengan masing-masing pada 70.64 ± 3.87, 66.26 ± 5.95, 76.61 ± 
3.99 and 81.39 ± 2.46% dalam OS-EL berbanding OS-E. OS-E dan OS-EL 
kemudiannya dikaji untuk aktiviti antihipertensi in vivo ke atas tikus SHR pada dos 
250 mg/kg/hari selama 28 hari. Captopril digunakan sebagai kawalan positif pada dos 
5 mg/kg/hari. Selain itu, aktiviti ACE-I ekstrak-ekstrak ini dalam plasma dan tisu SHR 
yang berbeza juga diukur selepas 28 hari rawatan melalui kaedah HPLC-UV yang 
dibangunkan. Keputusan menunjukkan bahawa, kedua-dua OS-E dan OS-EL mampu 
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menurunkan SBP (-23.08 ± 5.16 dan -28.96 ± 6.65) dan aktiviti ACE dalam plasma, 
aorta, jantung, paru-paru dan buah pinggang SHR secara signifikan. 
Walaubagaimanapun, OS-EL menunjukkan kesan antihipertensi yang lebih kuat (dan 
aktiviti penindasan ACE) berbanding OS-E. Kajian kestabilan dipercepatkan bagi OS-
E dan OS-EL yang disimpan pada empat suhu yang berbeza (30, 40, 50 dan 60 ° C) 
selama enam bulan telah dilakukan dengan menggunakan HPLC dan spektroskopi FT-
IR yang digabungkan dengan pendekatan kemometrik. Berdasarkan hasil kajian, 
sebatian penanda (RA, TMF, SIN dan EUP) dalam OS-E dan OS-EL adalah lebih 
stabil pada suhu rendah (30°C dan ke bawah). Kajian genotoksisiti akut dan ketoksikan 
subkronik OS-EL menunjukkan pengambilan OS-EL tidak menyebabkan kematian, 
tanda-tanda keracunan atau fungsi fisiologi dalam kedua-dua jantina haiwan. Data 
yang diperolehi daripada analisis pengekspresan miRNA menunjukkan bahawa dua 
miRNA; hsa-miR-149-3p dan hsa-miR-21-3p telah diekspres secara berbeza (kawal 
selia menaik) dalam HRGEC yang dirawat dengan OS-E dan OS-EL. miR-149 dan 
miR-21 mampu mensasarkan gen ACE dan AGTR1 secara langsung dan bertindak 
sebagai pengatur gen negatif. Oleh itu, boleh dicadangkan bahawa, OS boleh bertindak 
sebagai perencat ACE (ACE-I) dan penghalang reseptor angiotensin (ARBs). Sebagai 
kesimpulan, kajian ini memberikan bukti ke atas aktiviti antihipertensi, hubungan 
struktur aktiviti bagi sebatian penanda, kualiti dan keselamatan ekstrak terpiawai OS. 
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ANTIHYPERTENSIVE PROPERTIES OF STANDARDISED 
ORTHOSIPHON STAMINEUS BENTH. LEAVES EXTRACTS AND ITS 
NANO LIPOSOMES IN SPONTANEOUS HYPERTENSIVE RATS  
 
8 ABSTRACT 
This study was conducted to fulfill gaps between indigenous herbal practices and 
contemporary medicinal sciences on antihypertensive effect of Orthosiphon stamineus 
(OS) leaves. Quality and safety of the plant raw material were examined using 
gravimetric analysis and microbial limit test (MLT). OS leaves were found to be 
qualified in terms of physicochemical properties as well as microbial contamination. 
Spectroscopic (UV, FT-IR, FT-NIR) and chromatographic (HPTLC and HPLC) 
analyses were carried out on different extracts of OS for standardisation. The results 
showed that the major chemical constituents in OS extracts are phenolics and 
flavonoids such as rosmarininc acid (RA), 3-hydroxy-5, 6, 7, 4-methoxyflavone 
(TMF), sinensetin (SIN) and eupatorin (EUP). Furthermore, a gradient HPLC-DAD 
combined with solid-phase extraction technique was developed and validated for 
identification and quantification of 17 free amino acids in OS extracts. The results 
demonstrated that L-aspartic acid with 0.93 ± 0.01 nmol/mg and L-glutamic acid with 
4.01 ± 0.12 nmol/mg are the major free amino acid in OS extracts. Primary and 
secondary metabolites of OS extracts were analysed for their total flavonoids, 
polyphenols, phospholipids, proteins, polysaccharides and glycosaponins. The 
variation in the percentage of these metabolites in each extracts was indicated. 
Different extracts of OS and standard compounds (RA, TMF, SIN and EUP) were 
evaluated for in vitro assay of angiotensin converting enzyme inhibition (ACE-I). The 
results showed that, at final concentration of 50 µg/mL OS-E and EUP exhibit the 
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highest inhibition (52.67 ± 0.89 and 73.11 ± 2.39%, respectively) against ACE among 
extracts and tested standard compounds. Captopril was used as positive control and 
showed 86.14 ± 2.98% inhibition at concentration of 6.8 ng/mL. Chelation ability of 
Zn2+ by RA, TMF, SIN, EUP, captopril and OS-E was conducted using 
tetramethylmurexide (TMM) reagent. The results demonstrated that OS-E and 
captopril have a high ability (79.42 ± 1.91 and 100 ± 1.59%, respectively) to bind with 
Zn2+ at concentration of 5 mg/mL. Among the standard compounds, EUP shows the 
highest binding ability with Zn2+ (56.03 ± 1.26 %) at concentration of 5 mg/mL. In 
addition, the docking scores and binding affinities of marker compounds with Zn2+ in 
ACE were evaluated. The results showed that EUP has the highest binding affinity 
energy (ΔG) and ligand efficiency with -6.93 kcal/mol. Subsequently, OS-E extract 
was prepared in liposomal formulation using deoiled soya lecithin (OS-EL) and 
characterized versus different parameters. The results revealed production of nano 
liposomes of OS-E. The pharmacokinetics and oral bioavailability of RA, TMF, SIN 
and EUP in OS-E and OS-EL on Sprague Dawley (SD) rats indicated significant 
improvement in aqueous solubility and oral bioavailability of RA, TMF, SIN and EUP 
with 70.64 ± 3.87, 66.26 ± 5.95, 76.61 ± 3.99 and 81.39 ± 2.46%, respectively in OS-
EL compared to OS-E. OS-E and OS-EL were then studied for their in vivo 
antihypertensive activity on Spontaneous Hypertensive Rats (SHR) at dose of 250 
mg/kg/day for 28 days. Captopril was used as positive control at dose of 5 mg/kg/day. 
Moreover, ACE-I activity of these extracts in plasma and different tissues of SHR after 
28 days treatment was also measured using developed HPLC-UV method. The results 
demonstrated that both OS-E and OS-EL were able to reduce SBP (-23.08 ± 5.16 and 
-28.96 ± 6.65) and ACE activity in plasma, aorta, heart, lung and kidney of SHR 
significantly. However, OS-EL showed stronger antihypertensive effect (and 
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suppression of ACE activity) than OS-E. The accelerated stability studies of OS-E and 
OS-EL stored at four different temperatures (30, 40, 50 and 60°C) for six months were 
performed using HPLC and FT-IR spectroscopy combined with chemometric 
approach.  Based on the study findings, the marker compounds (RA, TMF, SIN and 
EUP) in both OS-E and OS-EL were more stable at lower temperature (30°C and 
below). The genotoxicity, acute and repeated dose oral toxicity study of OS-EL 
showed that administration of OS-EL does not cause death, visible signs of toxicity or 
other physiological functions in any animals of both sexes. The data obtained from 
miRNA expression analysis revealed that two miRNA; hsa-miR-149-3p and hsa-miR-
21-3p are expressed differently (up regulated) in HRGEC treated with OS-E and OS-
EL. miR-149 and miR-21 are able to directly target ACE and AGTR1 genes, 
respectively and act as negative gene regulators. It is suggested that OS could act ac 
ACE inhibitor (ACE-I) and angiotensin receptor blockers (ARBs). In conclusion, the 
current study provides evidence on antihypertensive activity, structure activity 
relationship of the active marker compounds, quality and safety of the standardised 
OS extract.  
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1 CHAPTER 1 
INTRODUCTION 
 
1.1 Herbal Medicines and Hypertension 
Herbal products as sources of medicine have been used for many years 
practically in all cultures. Consumption of herbal products has been increased 
significantly over the last decade (Ekor, 2014). This is probably because herbs are 
remarked as natural and therefore they are safe to use. Plants as an important source 
of new drugs development are still used, despite the extensive developments in 
synthetic chemistry. Several well-known medicines derived from plants include L-
hyoscyamine, morphine, colchincine, taxol anddigitoxin. Traditional medicines and 
herbal products for the primary health care are used by more than 80% of world 
population and mostly in developing countries (Hussain et al., 2009). In a period of 
1983-1994 in North America, about 40% of the new drugs were derived from natural 
compounds (Simmonds, 2003). Interestingly, over 70% of the new reported chemical 
in 1981-2006 were from the study of natural products (Newman and Cragg, 2007). 
Promoting and encouraging of the use of herbal products and remedies are 
recommended by World Health Organization (WHO) in the National Health Care 
Program (Hussain et al., 2009). 
Herbal products refer to organic chemicals that might come from a single plant 
or combination of more than one plant, from any raw or processed part of plant such 
as stems, leaves, roots, flowers and seeds. However, if they are combined with 
synthetic chemicals or other active substances, they are not considered as herbal 
medicines (WHO, 1996). Due to the presence of molecules and products that combat 
diseases in plants, they have played an important role in maintaining health. Many 
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products derived from plants in the form of dried plant materials, fresh or extracts are 
used as folk remedies. Different compounds derived from plant can be used as starting 
material for preparation of novel synthetic drugs. The potential of herbs as a source of 
new drugs has not been explored yet and only a limited number of plant species among 
250,000 have been investigated for their bioactive compounds (Borchardt, 2002) 
Traditional medicine has a number of proven benefits for prevention and cure of 
different ailments. Application of modern medicines along with traditional medicines 
made a strong comeback of herbs in many countries in the last decade (WHO, 1998). 
Appreciation of natural remedies might be due to the increment of the cost of treatment 
with modern medicines and fear of their side effects, which represents alternative 
healthcare movement. Due to this reason, the demand for herbal products has increased 
tremendously in the world market especially among young generation.  
The development of spectroscopic methods for the elucidation of natural 
compound structure together with development of biological sciences have opened a 
new era to study structure activity relationship. These developments have allowed for 
preparing derivatives or synthetic analogues using natural compounds as model.  
Hypertension or high blood pressure is one of the most important concerns in 
developed countries. It causes heart to work harder to maintain high blood pressure. 
Moreover, it contributes to atherosclerosis (hardening of arteries), besides increasing 
the risk of heart disease and stroke. Local plants, from different countries such as 
Agathosma betulina from Rutaceae family, Allium sativum from Alliaceae or Liliaceae 
family, Annona muricata from Annonaceae family, Apium graveolens from Apiaceae 
family, Aristolochia manshuriensis from Aristolochiaceae family, Artocarpus altilis 
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from Moraceae family, Coleus forskohlii from Lamiaceae family, have been widely 
used with hypotensive and antihypertensive therapeutic values to reduce high blood 
pressure (Tabassum and Ahmad, 2011). In Malaysia, Orthosiphon stamineus plant 
from Lamiaceae family have been used traditionally to cure hypertension (Perry, 
1998). However, scientific data to support its effect is not available. Therefore, more 
research coupled with modern medicine needs to be carried out to verify its 
effectiveness, and elucidate the safety profile of such herbal remedies for their 
hypotensive/antihypertensive potential. 
1.2 Standardisation of Herbal Medicine 
Standardisation is prescribing a set of standards or inherent characteristics, 
constant parameters, definitive qualitative and quantitative values that carry an 
assurance of quality, efficacy, safety and reproducibility. It is the process of 
developing and agreeing upon technical standards. Specific standards work out by 
experimentation and observations, which would lead to the process of prescribing a 
set of characteristics exhibited by a particular herbal medicine. Hence, standardisation 
is a tool in the quality control process. 
Several problems that are not applicable to synthetic drugs often influence the 
quality of herbal drugs. For instance: 1) herbal drugs are usually mixture of many 
constituents, 2) the active principle(s) is (are), in most cases unknown, 3) selective 
analytical methods or reference compounds may not be available commercially, 4) 
plant materials are chemically and naturally variable, 5) Chemo-varieties and chemo 
cultivars exist, 6) the source and quality of the raw materials are variable. Moreover, 
the light exposure, temperature, nutrients, use of fresh plants, age, part of the collected 
plant, water availability, period and time of collection, method of collecting, drying, 
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packing, storage, transportation, contamination with microorganism, heavy metals or 
pesticides, and processing (for example, mode of extraction and polarity of the 
extracting solvent, instability of constituents) might impact the quality, safety and 
efficacy of the herbal drugs (Calixto, 2000). In spite of many proven benefits of natural 
products, they cannot be widely accepted in the main stream of pharmaceuticals due 
to lack of standardisation. Therefore, it is necessary to provide scientific evidence on 
standardisation to support their efficacy and bring these remedies into the mainstream 
pharmaceutical market (Barnes, 2003).  
Due to the long-history of the use of herbal products in various cultures, they are 
usually considered safe. However, series of harmful effects after consumption of 
herbal products have been reported including direct toxic effect especially because of 
presence of heavy metal, allergic reactions, and mutagenic effects. In addition, the 
toxic effects of herbal preparation may be attributed to inherent toxicity of plant 
constituents, ingredients, manufacturing malpractice, and contamination 
(Mosihuzzaman and Choudhary, 2008). Therefore, standardisation and quality control 
of the raw materials and herbal preparation are necessary to be carried out.  
Numbers of International Pharmacopoeia such as British Pharmacopoeia and  
United States Pharmacopeia, which contained collection of recommended procedures 
such as macroscopic and microscopic examination, determination of total ash, acid-
insoluble ash and water-soluble ash, determination of pesticide residue, determination 
of swelling and foaming index, limit test for heavy metals, limit test for 
microorganisms, and test for determination of extractable matter, water and volatile 
matterfor specifications and quality control of plant raw materials, have been 
conducted by WHO (WHO, 1973). Moreover, many international authorities and 
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agencies including the European Agency for Evaluation of Medicinal Products and the 
European Scientific Cooperation of Phytomedicine, The US Agency for Healthcare 
Policy, and Research the European Pharmacopoeia Commission have started creating 
a new mechanism for quality control and standardisation of botanical medicines 
(Sharma et al., 2010). 
1.3 Justification of the Research 
In this study, Orthosiphon stamineus (OS) a local plant was selected for studying 
its antihypertensive effect. O. stamineus known as misai kucing is a medicinal plant 
grown in South East Asia and currently cultivated in Indonesia and Malaysia. In 
Malaysia, the leaves of this plant (misai kucing) have been used traditionally in treating 
angiogenesis related diseases, urinary lithiasis, edema, inflammation, eruptive fever, 
influenza, hepatitis, jaundice, rheumatism, diabetes and hypertension (Mukesh et al., 
2015; Perry, 1998). Recent scientific findings also showed that O. stamineus have the 
potential for different pharmacological properties. Although a number of products 
manufactured from O. stamineus are available in the market, there is still lack of 
information in terms of chemical components related to primary metabolites such as 
content of specific amino acids. The basis for the traditional use of this herb as 
antihypertensive and structure activity relationship has not yet been scientifically 
verified. Furthermore, a new step in development of new generation of standardised 
herbal medicine is preparation of botanical formulation to increase the solubility and 
bioavailability of the active constituents with therapeutic activity. In addition, 
microRNAs, as candidates for diagnostic and prognostic biomarkers and predictors of 
this herb response, have not yet been investigated. Therefore, this research aims to 
fulfil the gaps between indigenous herbal practices and contemporary medicinal 
sciences.  
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1.4 General Objectives 
This study generally seeks to standardise O. stamineus leaves extracts by 
developing new analytical techniques to measure the content of primary and secondary 
metabolites in O. stamineus extracts. Moreover, it aims to demonstrate the in vitro and 
in vivo antihypertensive properties of standardised O. stamineus extracts based on 
structure activity relationship of marker compounds. In addition, it seeks to prepare 
new formulation from standardised O. stamineus extract using soy bean phospholipids 
in order to improve the solubility and bioavailability of the active constituents with 
therapeutic activity. It also aims to utilize expression of miRNA subsets as a new tool 
to elucidate the mechanism of plant in treatment of hypertension.  
1.5 Specific Objectives  
1) To standardise Orthosiphon stamineus extracts using selected markers by 
developing new analytical methods. 
2) To evaluate antihypertensive properties of the various standardised extracts of 
Orthosiphon stamineus based on structure activity relationship of marker 
compounds. 
3) To prepare nano liposomes of the most active extract in order to improve 
antihypertensive activity, solubility and bioavailability of the active marker 
compounds. 
4) To determine pharmacokinetic, stability, acute and sub chronic toxicity studies of 
the nano liposomes of Orthosiphon stamineus extract. 
5) To investigate the expression of miRNA subsets as potential biomarkers for 
antihypertensive activities. 
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1.6 Hypotheses 
O. stamineus has been used in traditional medicine to treat hypertension. 
Subsequently, presence of high content of phenolics and flavonoids compounds such 
as sinensetin (SIN), eupatorin (EUP), 3'-hydroxy-5, 6, 7, 4’-tetramethoxy flavone 
(TMF) and rosmarinic acid (RA) were detected in O. stamineus extract in previous 
studies. Whereas, inhibition activity of angiotensin converting enzyme (ACE) has 
been attributed to the presence of flavonoids in the plant extract, due to the generation 
of chelate complexes within the active centre of ACE. Therefore, possible research 
hypothesis would be that there is a correlation between the presence of these 
compounds and antihypertensive properties of the plant. 
1.7 Significance of Study  
The findings of this study provide knowledge on application of analytical 
methods for standardisation of plant materials and extract to produce, safe and high 
quality herbal medicinal products for manufacturers and consumers. Moreover, this 
research fills the gaps between indigenous herbal practices and contemporary 
medicinal sciences on antihypertensive effect of medicinal plant. Additionally, this 
study is a significant endeavour in promoting the use of natural phospholipid bilayer 
obtained from food grade soybean lecithin to prepare new botanical formulation to 
improve the extract’s solubility and permeability as the major factors for improving 
oral bioavailability.  
1.8 Methodology Flowchart  
The overall methodology consists of many steps, which includes quality test of 
raw material by gravimetric analysis, extractive value, heavy metals and microbial 
limit test. The plant raw materials will be extracted by maceration method to prepare 
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water (OS-W), ethanolic (OS-E), methanolic (OS-M), 50% ethanolic (OS-EW) and 
50% methanolic (OS-MW) extracts. All extracts will be standardised by different 
spectroscopic and chromatographic techniques (UV-Vis, FT-IR, FT-NIR, HPTLC and 
HPLC). Moreover, the contents of primary and secondary metabolites also will be 
quantified in the extracts. The molecular docking study will be carried out on the 
marker compounds of extracts to determine the docking scores and binding affinities 
of marker compounds with Zn2+ in angiotensin converting enzyme. Then in vitro 
angiotensin converting enzyme inhibitory (ACE-I) assays including enzymatic ACE-
I assay and chelating activity of Zn+2 will be studied on extract and marker compounds. 
Two extracts with highest ACE-I activity will be screened for in vivo antihypertensive 
properties on Spontaneous Hypertensive Rats (SHR) in order to select the best extract 
with highest antihypertensive activity. The most active extract will be formulated using 
soy been phospholipids in order to improve the solubility and bioavailability of the 
active constituents with therapeutic activity. Subsequently, the nano formulated extract 
will be characterized for different parameters. Moreover, pharmacokinetic, stability 
and toxicology studies will be done on nano formulated extract. Then, in vivo anti-
hypertension activity of nano formulated extract will be studied on SHR. At the end, 
miRNA expression study will be done to investigate the expression of miRNA subsets 
as potential biomarkers for antihypertensive activities. The methodology of this study 
is summarized in the following flowchart (Figure 1.1).  
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Figure 1.1: Methodology flowchart 
  
Procurement of O. stamineus leaves materials 
Drying and grinding them into powder 
Quality testing of raw materials by gravimetric analysis, 
extractive value, heavy metal and microbial test teast  
Extraction using maceration method with water, ethanol, 
methanol, 50% ethanol and 50% methanol 
UV-Vis, FT-IR, FT-NIR 
and HPTLC 
HPLC Determining of primary and 
secondary metabolites  
Standardising crude extracts 
In vitro angiotensin converting 
enzyme inhibitory (ACE-I) assays 
 
Enzymatic ACE-I assay on 
extracts and marker compounds 
In vivo antihypertensive 
activity of extracts on SHR 
 
Chelating activity of Zn+2 by 
extract and marker compounds 
Molecular docking study 
Selecting the best extract with highest antihypertensive activity 
Preparation and characterization of nano formulation using 
deoiled soya lecithin 
Pharmacokinetic, stability and toxicology study 
 
In vivo anti-hypertension study of nano formulated extract on SHR 
miRNA expression analysis 
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2 CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Orthosiphon stamineus 
2.1.1 Taxonomy 
Taxonomically, this plant is classified as the following scheme:  
Family                     Lamiaceae 
Genus Orthosiphon 
Scientific name Orthosiphon stamineus. (Benth) 
Local name Misai Kucing 
Synonyms O. aristatus (Bl.); O. grandiflorus, Bold., O. spicatus 
Common name Java tea, cat’s whiskers 
(Comprehensive information about Orthosiphon stamineus plant can be found at 
http://www.ars-grin.gov/cgi-bin/npgs/html/taxon.pl?423487) 
Orthosiphon stamineus Benth is a well-known medicinal plant belonging to 
Lamiaceae family. This plant is native in Southeast Asian countries. It is a perennial 
herb, 25-200 cm tall with quadrangular, poorly ramified and ascending stem. The plant 
is herbaceous shrub and it can be found in tropical and sub tropical regions. The stem 
is acutely quadrangular, reddish in colour, erect and branches profusely. The leaves 
are simple, green and glabrous with a lanceolate leaf blade and serrate margin. The 
leaves are arranged in opposite pairs and the petiole is short about 1.3 cm in length and 
reddish purple in colour. The flowers are hermaphrodite, about 6.2 cm in length 
including the staments, with very irregular flower symmetry (Almatar et al., 2013). In 
South East Asia, this plant is known as misai kucing (Malaysia), kumis kucing and 
11 
 
remujung (Indonesia) and yaa nuat maeo (Thailand). In Malaysia, the local name of 
this plant refers to the white or blue colour of flowers with long filaments over mid-
green foliage which makes the flower look like cat’s whiskers in Malay Misai 
(whiskers) kucing (cat) (Figure 2.1).  
2.1.2 Ethnopharmacology 
O. stamineus has been traditionally used for treating ranges of diseases such as 
edema, inflammation, urinary, lithiasis, hepatitis, rheumatism, eruptive fever, diabetes, 
influenza, jaundice, as a remedy for kidney stones and nephritis, pain in the bladder 
with frequent urination, diuretic, biliary and hypertension (Awale et al., 2001; Dat et 
al., 1992; Goh et al., 1995; Tezuka et al., 2000). Leaves of this plant in Southeast Asian 
and European countries are used popularly as herbal tea, known as “Java tea”.  
 
Figure 2.1: Pictures of Orthosiphon stamineus leaves and flower 
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2.2 Review of Chemical Constituents of Orthosiphon stamineus 
Phytochemically, the plant is rich in flavonoids especially polymethoxylated 
flavone, terpenes, diterpenoids and triterpenes such as hydroxyl betulinic acid, 
betulinic acid, oleanolic acid, ursolic acid and caffeic acid derivatives like rosmarinic 
acid (Sumaryono et al., 1991). The chemical constituents and chemical structure 
identified in the aerial parts of O. stamineus are illustrated in Table 2.1 and Table 2.2. 
Table 2.1: Chemical constituents of Orthosiphon stamineus 
Class of compounds Part of plant Chemical constituents Reference 
Diterpenes  Aerial  Orthisiphols F [1], orthosiphols 
G [2], orthosiphols H [3], 
orthosiphol I [4], orthosiphol J 
[5], orthosiphol S [6], staminols 
A [7], staminols B [8], 
staminolactones A [9], 
staminolactones B [10], 
norstaminol A [11], 
orthosiphonone A [12], 
orthosiphonone B [13]  
(Awale et al., 
2001; Tezuka 
et al., 2000) 
    
Triterpenes  Aerial Oleanolic acid [14], ursolic acid 
[15], betulinic acid [16], β-
sitosterol [17]  
(Tezuka et al., 
2000) 
Flavones  Aerial  7,3',4'-tri-O-methylluteolin [18], 
eupatorin [19], sinensetin [20], 
3'-hydroxy-5,6,7,4'-
tetramethoxyflavone [21], 
salvigenin [22], ladanein [23], 
scutellarein tetramethyl ether 
[24], 6-hydroxy-5,7,4'-
trimethoxyflavone [25], 
kaempferol-3-O-β-glucoside 
[26], quercetin-3-O-β-glucoside 
[27] 
(Sumaryono et 
al., 1991; 
Tezuka et al., 
2000) 
Phenolic acids Leaves Caffeoyl tartrate [28], rosmarinic 
acid [29], aurantiamide acetate 
[30], vomifoliol [31], caffeic 
acid [32], 2,3-dicaffeoyl tartrate 
[33] 
(Sumaryono et 
al., 1991) 
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Table 2.1: Continued 
Benzochromene Leaves Methylripariochromene A [34], 
acetovanillochromene [35], 
orthochromene A [36] 
(Shibuya et 
al., 1999) 
Number in brackets indicate the number of the structure  
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Table 2.2: Chemical structures of Orthosiphon stamineus 
   
Orthosiphol F [1] Orthosiphol G [2] Orthosiphol H [3] 
  
 
Orthosiphol I [4] Orthosiphol J [5] Orthosiphol S [6] 
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Table 2.2: Continued 
   
Staminol A [7] Staminol B [8] Staminolactone A [9] 
  
 
Staminolactone B [10] Norstaminol A [11] Orthosiphonone A [12] 
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Table 2.2: Continued 
 
Orthosiphonone B [13] 
 
Oleanolic acid [14] 
 
Ursolic acid [15] 
 
Betulinic acid [16] 
 
β-sitosterol [17] 
 
 
7,3’,4’-tri-O-methylluteolin [18] 
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Table 2.2: Continued 
 
Eupatorin [19] 
 
Sinensetin [20] 
 
3ʹ-hydroxy-5,6,7,4ʹ-tetramethoxyflavone 
[21] 
 
Salvigenin [22] 
 
Ladanein [23] 
 
Scutellarein tetramethyl ether [24] 
 
18 
 
Table 2.2: Continued 
 
 
6-Hydroxy-5,7,4ʹ-trimethoxyflavone [25] 
 
Kaempferol-3-O-β-glucoside [26] 
 
Quercetin-3-O-β-glucoside [27] 
 
 
Caffeoyl tartrate [28] 
 
Rosmarinic acid [29] 
 
Aurantiamide acetate [30] 
 
